Spots Global Cancer Trial Database for anaplastic lymphoma kinase
Every month we try and update this database with for anaplastic lymphoma kinase cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of Brigatinib to Treat Adults With Anaplastic Lymphoma Kinase (ALK) Positive Metastatic Non Small Cell Lung Cancer (NSCLC) | NCT04887519 | Carcinoma, Non-... Anaplastic Lymp... | No Intervention | 18 Years - | Takeda | |
| A Real World Study of Ensartinib in Advanced ALK-positive NSCLC | NCT05498064 | Carcinoma, Non-... Anaplastic Lymp... Ensartinib | Ensartinib | 18 Years - | Peking Union Medical College Hospital | |
| Expanded Access to Ensartinib for Participants With ALK+ NSCLC | NCT04146571 | Non-Small Cell ... ALK Gene Rearra... | Ensartinib | 18 Years - | Xcovery Holdings, Inc. | |
| Lorlatinib Continuation Study | NCT05144997 | Non-Small-Cell ... NSCLC | Lorlatinib | 18 Years - | Pfizer | |
| Phase II Study of SY-3505 in Patients With ALK-positive NSCLC Who Have Failed Prior Second-Generation ALK TKI | NCT05869162 | Non-small-cell ... | SY-3505 | 18 Years - | Shouyao Holdings (Beijing) Co. LTD | |
| A Study Of SY-3505 Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC | NCT06254599 | Non-small Cell ... | SY-3505 Capsule... Crizotinib Caps... | 18 Years - | Shouyao Holdings (Beijing) Co. LTD | |
| Lorlatinib Continuation Study | NCT05144997 | Non-Small-Cell ... NSCLC | Lorlatinib | 18 Years - | Pfizer | |
| Crizotinib Continuation Clinical Study | NCT05160922 | NSCLC ALCL IMT | crizotinib | 1 Year - 99 Years | Pfizer | |
| Ceritinib Rare Indications Study in ALK+ Tumors | NCT02465528 | Tumors With Abe... Anaplastic Larg... Inflammatory My... Glioblastoma | Ceritinib (LDK3... | 18 Years - | Novartis | |
| An Investigational Drug, Crizotinib (PF-02341066), Is Being Studied In Tumors, Except Non-Small Cell Lung Cancer, That Are Positive For Anaplastic Lymphoma Kinase (ALK) | NCT01121588 | Neoplasms Malig... | Crizotinib | 15 Years - | Pfizer | |
| Ceritinib Rare Indications Study in ALK+ Tumors | NCT02465528 | Tumors With Abe... Anaplastic Larg... Inflammatory My... Glioblastoma | Ceritinib (LDK3... | 18 Years - | Novartis | |
| A Prospective Epidemiologic Study of ALK-Positive NSCLC in China | NCT02042105 | Non-small-cell ... | 18 Years - | Guangdong Association of Clinical Trials | ||
| A Pilot Study on ALK Gene Mutations in Neuroblastoma | NCT01986595 | Neuroblastoma | - 50 Years | National Taiwan University Hospital | ||
| A Phase I/IIa Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients With Advanced Solid Tumors and Lymphomas | NCT02048488 | Solid Tumors Lymphomas | TSR-011 | 18 Years - | Tesaro, Inc. | |
| Crizotinib Continuation Clinical Study | NCT05160922 | NSCLC ALCL IMT | crizotinib | 1 Year - 99 Years | Pfizer | |
| Crizotinib Continuation Clinical Study | NCT05160922 | NSCLC ALCL IMT | crizotinib | 1 Year - 99 Years | Pfizer | |
| A Pilot Study on ALK Gene Mutations in Neuroblastoma | NCT01986595 | Neuroblastoma | - 50 Years | National Taiwan University Hospital | ||
| Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer | NCT02521051 | Non-Small Cell ... | Alectinib Bevacizumab | 18 Years - | Massachusetts General Hospital | |
| A Prospective Epidemiologic Study of ALK-Positive NSCLC in China | NCT02042105 | Non-small-cell ... | 18 Years - | Guangdong Association of Clinical Trials |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
